RVTY logo

Revvity, Inc. Stock Price

NYSE:RVTY Community·US$11.4b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 14 Fair Values set on narratives written by author

RVTY Share Price Performance

US$0
-90.50 (-100.00%)
US$113.64
Fair Value
US$0
-90.50 (-100.00%)
Price US$0

RVTY Community Narratives

·
Fair Value US$113.64 13.4% undervalued intrinsic discount

RVTY: Operating Margins And Buyback Plan Will Drive Share Recovery Ahead

0users have liked this narrative
0users have commented on this narrative
8users have followed this narrative
·
Fair Value US$95 3.5% overvalued intrinsic discount

Regulatory Shifts Will Pressure Diagnostics Yet Spur Measured Turnaround

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
·
Fair Value US$140 29.7% undervalued intrinsic discount

Genomics And Automation Will Expand Diagnostics In Aging Populations

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
US$95
3.5% overvalued intrinsic discount
Revenue
5.34% p.a.
Profit Margin
20.88%
Future PE
16.57x
Price in 2029
US$121.08
US$140
29.7% undervalued intrinsic discount
Revenue
6.36% p.a.
Profit Margin
19.94%
Future PE
24.84x
Price in 2029
US$178.42

Trending Discussion

Updated Narratives

RVTY logo

RVTY: Q1 Execution And Tools Demand Will Support Measured Future Earnings Power

Fair Value: US$113.64 13.4% undervalued intrinsic discount
8 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
RVTY logo

RVTY: Cautious 2026 Tools Recovery Setup Will Face Execution Debate

Fair Value: US$95 3.5% overvalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
RVTY logo

RVTY: Recent Upgrade Cycle And Q4 Execution Will Drive Future Upside

Fair Value: US$140 29.7% undervalued intrinsic discount
0 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Adequate balance sheet and fair value.

1 Risk
2 Rewards

Revvity, Inc. Key Details

US$2.9b

Revenue

US$1.3b

Cost of Revenue

US$1.6b

Gross Profit

US$1.3b

Other Expenses

US$239.1m

Earnings

Last Reported Earnings
Apr 05, 2026
Next Reporting Earnings
n/a
2.14
54.32%
8.24%
44.7%
View Full Analysis

About RVTY

Founded
1937
Employees
11000
CEO
Prahlad Singh
WebsiteView website
www.revvity.com

Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.

Recent RVTY News & Updates

Narrative Update Jun 01

RVTY: Q1 Execution And Tools Demand Will Support Measured Future Earnings Power

Revvity's updated analyst price target has shifted to $113.64 from $119.56. This reflects a mix of recent target cuts and raises as analysts factor in revised growth and profitability assumptions, as well as a higher future P/E outlook.

Recent updates

No updates